Newer Frontiers in Urology, Volume II

Bridging Molecular Insights and Technological Innovation: The Emerging Frontiers in Urology

Venkateshen Palaniyandi, Sriram Krishnamoorthy — Tue, 27 Jan 2026 00:00:00 +0000

Background: Urology has undergone a profound transformation over the past decade, evolving from a discipline centred on anatomy and conventional surgery into one driven by molecular diagnostics, technological innovation, and digital intelligence. Advances in immunohistochemistry, genomic profiling, minimally invasive and robotic surgery, regenerative medicine, and artificial intelligence (AI) have collectively reshaped disease understanding, diagnosis, and management.

Objective: This work aims to synthesise contemporary advances in urology by highlighting how molecular precision, surgical innovation, and data-driven technologies converge to deliver personalised, predictive, and precision-based patient care.

Methods: This narrative synthesis integrates evidence and thematic insights from multiple subdomains of modern urology, including molecular pathology in bladder cancer, endourological and robotic surgical innovations, regenerative and reproductive sciences, and AI-driven clinical decision support systems. Conceptual frameworks and representative clinical applications described across the chapters of this volume are analysed to illustrate translational integration.

Results: Molecular diagnostics, particularly immunohistochemistry and biomarker profiling such as HER2, have shifted pathology from descriptive morphology to functional, prognostic decision-making. Technological innovations in endourology and robotics have standardised and refined surgical practice through classification systems, advanced optics, and laser technologies. Regenerative and reproductive urology now incorporates molecular endocrinology, microbiome science, antioxidants, and stem cell-based approaches. AI and machine learning models enable rapid risk stratification, image interpretation, surgical guidance, and outcome prediction, supporting complex clinical decisions while maintaining transparency and accountability.

Conclusion: Modern urology represents a translational convergence of biology, technology, and data science. The field is transitioning from reactive care to proactive, individualised management while emphasising ethical practice, standardisation, and equitable access. This integrated approach defines the future of urology, balancing technological advancement with clinical judgment and patient-centred care.

Immunohistochemistry in Bladder Cancer: Diagnostic, Prognostic, and Molecular Subtyping Applications

Tue, 27 Jan 2026 00:00:00 +0000

Introduction: Immunohistochemistry (IHC) has evolved from a primarily diagnostic adjunct to a central component of precision oncology in bladder cancer. By bridging histomorphology with molecular characterisation, IHC contributes to diagnosis, prognostication, staging, and therapeutic decision-making. However, variability in marker selection, interpretation, and standardisation remains a challenge in routine practice.

Aim: This chapter aims to provide a focused overview of the role of IHC in bladder cancer, addressing current gaps in consistent application while highlighting its diagnostic utility, prognostic and predictive significance, role in molecular subtyping, and integration with emerging technologies.

Key Points: IHC facilitates accurate detection of carcinoma in situ, molecular luminal–basal subtyping, and refined staging using markers such as CK20, GATA3, CK5/6, and smoothelin. Prognostic markers, including Ki-67 and p53, and predictive biomarkers such as PD-L1 and HER2, demonstrate increasing clinical relevance, with reported diagnostic and prognostic accuracies supporting their use in selected settings. The integration of multi-marker panels, digital pathology, and molecular diagnostics enhances reproducibility and precision, though limitations related to inter-observer variability, assay standardisation, and evolving biomarker validation persist.

Conclusion: IHC remains a cornerstone of bladder cancer pathology, underpinning diagnostic accuracy and therapeutic stratification. With ongoing innovations in biomarker discovery, artificial intelligence, and standardisation, IHC continues to evolve as a critical platform for translational and clinical application in urologic oncology.

HER2 in Bladder Cancer: Molecular Biology, Prognostic Value, and Emerging Therapeutic Strategies

Tue, 27 Jan 2026 00:00:00 +0000

Introduction: Non-muscle invasive bladder cancer (NMIBC) accounts for nearly 75–80% of newly diagnosed bladder cancers and is marked by frequent recurrence and a variable risk of progression. Human epidermal growth factor receptor 2 (HER2) has emerged as a biologically relevant oncogenic driver in urothelial carcinoma, but its prognostic and therapeutic significance in NMIBC remains incompletely defined.

Aim: This review synthesises current evidence on HER2 biology, molecular associations, prognostic relevance, and therapeutic implications in bladder cancer, with a focus on NMIBC.

Results: HER2 overexpression and amplification are enriched in high-grade tumours, advanced stages, luminal molecular subtypes, and aggressive histological variants, and are associated with disease progression and resistance to intravesical BCG therapy. Despite strong biological rationale, conventional HER2-targeted therapies have shown limited efficacy in urothelial carcinoma due to heterogeneous expression, discordance between protein overexpression and gene amplification, and complex downstream signalling. In contrast, emerging antibody–drug conjugates demonstrate promising clinical activity, including in tumours with low or heterogeneous HER2 expression.

Conclusion: HER2 represents a clinically meaningful biomarker and therapeutic target in bladder cancer. Standardised HER2 assessment integrated with molecular profiling may refine risk stratification and enable precision-guided therapies, particularly for patients with high-risk or treatment-refractory NMIBC.

Scoring Systems for Inflammatory and Traumatic Urethral Strictures

Tue, 27 Jan 2026 00:00:00 +0000

Introduction: Urethral stricture disease in males presents a spectrum of complexity depending on aetiology and location. Inflammatory strictures and traumatic strictures pose unique challenges. Historically, the lack of a standardised classification has hindered the comparison of treatment outcomes and consensus in management.

Aim: To review and describe the major scoring systems developed for urethral strictures, specifically those arising from inflammatory and traumatic causes, and to discuss their clinical utility in guiding management.

Findings: Three principal scoring/classification systems are in use. The U-score is a numeric composite for anterior strictures based on stricture length, number, location, and aetiology. The LSE classification is a standardised staging for anterior urethral strictures, treating stricture attributes akin to a TNM-like categorisation. The PU-score applies to posterior strictures, assigning points for injury factors such as aetiology, location, defect length, and associated complications. Higher scores have been correlated with more complex surgeries and increased risk of recurrence. The PU-score likewise predicts surgical complexity and outcomes in posterior injuries.

Conclusion: Scoring systems for urethral strictures help stratify disease severity and guide management decisions. They facilitate standardised communication of structural complexity, inform surgical planning (one-stage vs multi-stage reconstruction), and allow outcome comparisons across studies. While promising, each system has limitations, and ongoing refinement and validation are needed before universal adoption in routine practice.

Supine Percutaneous Nephrolithotomy (PCNL): Current Status

Tue, 27 Jan 2026 00:00:00 +0000

Background: Percutaneous nephrolithotomy (PCNL) remains the standard treatment for large (>20 mm), staghorn, and complex renal calculi. Although the prone position has traditionally been preferred, it is associated with anaesthetic challenges, longer operative times due to repositioning, and ergonomic limitations. Supine PCNL, particularly in the Galdakao-modified supine Valdivia position, has re-emerged as an alternative that may improve perioperative safety, workflow efficiency, and facilitate combined antegrade–retrograde intrarenal surgery (ECIRS).

Objective: To review the current status of supine PCNL, focusing on its procedural principles, indications, outcomes, complications, and comparative effectiveness relative to prone PCNL.

Methods: A narrative review was performed synthesising evidence from comparative studies, randomised trials, meta-analyses, and large observational series evaluating supine PCNL. Key aspects analysed included patient selection, positioning techniques, access and tract creation, intraoperative workflow, adjunctive ECIRS, anaesthetic and ergonomic considerations, postoperative strategies, and reported clinical outcomes.

Results: Across most indications, supine PCNL demonstrates stone-free and complication rates comparable to prone PCNL. Supine positioning consistently reduces operative and anaesthesia time by eliminating intraoperative repositioning and improves airway access and hemodynamic stability, particularly in obese and high-risk patients. ECIRS is more readily feasible in the supine position, narrowing any potential disadvantage in complete staghorn calculi. Bleeding, infection, and visceral injury rates are similar between positions when appropriate patient selection and imaging-guided access are employed.

Conclusion: Supine PCNL is a safe, efficient, and versatile alternative to prone PCNL that aligns with contemporary goals of patient-centred care, anaesthetic safety, and surgical ergonomics. With appropriate training and case selection, it achieves outcomes equivalent to the prone approach while offering distinct workflow and physiologic advantages.

Innovations in Flexible Ureterorenoscopy for Renal Stones

Tue, 27 Jan 2026 00:00:00 +0000

Background: Flexible ureterorenoscopy (fURS) has become a cornerstone in the minimally invasive management of renal stone disease. Continuous technological evolution over the past decades has expanded its indications, improved procedural safety, and enhanced stone-free outcomes. This review synthesises recent innovations that have reshaped contemporary fURS practice.

Objective: To critically appraise key technological and procedural advances in flexible ureterorenoscopy, with emphasis on scope design, laser lithotripsy, adjunctive instrumentation, and emerging guidance and robotic systems, and to evaluate their clinical impact on renal stone management.

Methods: A narrative review was conducted based on historical milestones, recent clinical studies, systematic reviews, and meta-analyses addressing innovations in fURS. Developments in digital and single-use ureteroscopes, laser technologies, ureteral access sheaths, irrigation and pressure-control systems, image guidance, and robotic assistance were analysed with respect to efficacy, safety, and workflow implications.

Results: Major advancements include the transition to high-definition digital “chip-on-tip” ureteroscopes, the widespread adoption of single-use disposable scopes, and enhanced deflection mechanisms that improve access to complex calyceal anatomy. Laser innovations, particularly thulium fibre lasers and pulse-modulated holmium systems, have increased fragmentation efficiency while reducing retropulsion and operative time. Suction-enabled and pressure-controlled ureteral access sheaths have improved stone clearance and reduced infectious complications. Emerging technologies such as augmented reality navigation and robotic-assisted fURS have demonstrated stone-free rates comparable to those of conventional techniques while significantly improving surgeon ergonomics.

Conclusion: Technological innovation has transformed fURS into a highly effective, safe, and versatile modality for the treatment of renal stones. Ongoing integration of advanced lasers, innovative instrumentation, image guidance, and robotics is likely to refine outcomes further, personalise treatment strategies, and establish new benchmarks in endourological care.

Angiogenesis in Renal Cell Carcinoma: Molecular Biology, Clinical Manifestations, and Case-Based Insights

Tue, 27 Jan 2026 00:00:00 +0000

Angiogenesis is the defining biological feature of clear-cell renal cell carcinoma (ccRCC). Loss of Von Hippel–Lindau (VHL) function stabilises hypoxia-inducible factors (HIFs), upregulating vascular endothelial growth factor (VEGF) and allied mediators that produce a hypervascular, leaky, and fragile tumour vasculature. This chapter offers a concise, clinically oriented review of renal cell carcinoma (RCC) angiogenesis centred on an exceptional case: a right-sided ccRCC with intratumoral arteriovenous (AV) shunting and venous collaterals that communicated with the second part of the duodenum, presenting as severe upper gastrointestinal (GI) bleeding. We translate the mechanism into management, emphasising rapid stabilisation, diagnostic angiography, endovascular embolisation, and definitive surgery; then situate contemporary systemic therapy [VEGF/VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs), immuno-oncology–TKI (IO–TKI) combinations, and HIF-2α inhibition] within decision frameworks that clinicians can apply. An expanded discussion links vessel biology to imaging signatures, resistance, perioperative strategies, and follow-up care. This case serves as a central framework for demonstrating how timely, multidisciplinary coordination can prevent catastrophic haemorrhage and ensure durable oncological control.

Renal Papillary Necrosis in Acute Pyelonephritis: Pathogenesis, Diagnosis, and the Role of Relook Flexible Ureterorenoscopy

Tue, 27 Jan 2026 00:00:00 +0000

Renal papillary necrosis (RPN) is an under-recognised complication of acute pyelonephritis (APN), especially in high-risk populations like diabetics. This chapter explores the vascular and infectious pathophysiology underlying RPN, describes its classic and atypical presentations, and highlights the emerging role of relook flexible ureterorenoscopy (F-RURS) in identifying and removing necrosed papillae. Recent case reports and small series suggest that timely endoscopic removal of necrotic debris reduces recurrence and improves renal outcomes. This chapter aims to equip clinicians with a structured approach to suspect, investigate, and intervene upon RPN in the APN setting.